FDA Accepts Dr. Magoola’s Application for Generic Bone Drug

FDA accepts Dr. Magoola’s application for generic bone drug

Kampala — Ugandan pharmaceutical manufacturer Dei Biopharma led by scientist Dr. Matthias Magoola has received a significant boost in its bid to enter the highly regulated United States drug market after the U.S. Food and Drug Administration (FDA) accepted its application for a generic osteoporosis drug for substantive review just three days after submission. The FDA accepted DEI Biopharma’s Abbreviated New Drug Application (ANDA) for teriparati…

Dr. Magoola gets FDA boost for rare borne drug in US market

Dr. Matthias Magoola and Dei Biopharma have received a significant boost after the U.S. FDA accepted their application for a generic version of the osteoporosis drug Forteo. The move signals strong confidence in the Ugandan company’s scientific rigor and complex injectable drug pipeline. KAMPALA — Ugandan pharmaceutical manufacturer Dei Biopharma led by scientist Dr. Matthias Magoola has received a significant boost in its bid to enter the highl…